Maintenance Notice (4:30 AM - 11:00 AM December 21, 2024): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.197
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 132539-06-1 | Product Number: O0393
Olanzapine
×
![]()
×
Purity: >98.0%(GC)(T)
Synonyms:
- 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 1G |
€58.00
|
4 | 32 |
|
| 5G |
€184.00
|
2 | ≥60 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | O0393 |
| Purity / Analysis Method | >98.0%(GC)(T) |
| Molecular Formula / Molecular Weight | C__1__7H__2__0N__4S = 312.44 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 132539-06-1 |
| Reaxys Registry Number | 7655141 |
| PubChem Substance ID | 160871343 |
| Merck Index (14) | 6822 |
| MDL Number | MFCD00866702 |
Specifications
| Appearance | Light yellow to Amber to Dark green powder to crystal |
| Purity(GC) | min. 98.0 % |
| Purity(Nonaqueous Titration) | min. 98.0 % |
Properties (reference)
| Melting Point | 194 °C(dec.) |
| Solubility in water | Insoluble |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H301 : Toxic if swallowed. H315 : Causes skin irritation. H319 : Causes serious eye irritation. H413 : May cause long lasting harmful effects to aquatic life. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P273 : Avoid release to the environment. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. |
Related Laws:
| RTECS# | XJ9007750 |
Transport Information:
| UN Number | UN2811 |
| Class | 6.1 |
| Packing Group | III |
| HS Number | 2934999090 |
Application
Bone research
References
- Atypical antipsychotics induce human osteoblasts apoptosis via Wnt/β-catenin signaling
- Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients
Application
Olanzapine: A Multi-Acting Receptor Targeted Antipsychotic (MARTA)
Olanzapine is known as a multi-acting receptor targeted antipsychotic (MARTA), such as clozapine [C2547] and quetiapine [Q0092]. Olanzapine has greater affinity for serotonin 5-HT2A and dopamine D2 receptors. Furthermore, olanzapine has various affinities for multiple receptors, including serotonin 5-HT2C, 5-HT6 receptors, dopamine D1-4, histamine H1, and adrenergic α1 receptors. In addition, olanzapine has moderate affinity binding for serotonin 5HT3 and muscarinic M1-5. While, olanzapine binds weakly to GABAA, benzodiazepine (BZD), and β-adrenergic receptors. The precise mechanism of action is unknown, but olanzapine is used as a thienobenzodiazepine atypical antipsychotic.
Recently, it is reported that the use of olanzapine combined with a 5-HT3 receptor antagonist, a neurokinin1 (NK1) receptor antagonist and dexamethasone [D1961] has improved the control of acute chemotherapy-induced nausea and vomiting. (The product is for research purpose only.)
Recently, it is reported that the use of olanzapine combined with a 5-HT3 receptor antagonist, a neurokinin1 (NK1) receptor antagonist and dexamethasone [D1961] has improved the control of acute chemotherapy-induced nausea and vomiting. (The product is for research purpose only.)
References
- Radioreceptor binding profile of the atypical antipsychotic olanzapine
- Binding of antipsychotic drugs to human brain receptors - focus on newer generation compounds
- 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release
- Olanzapine: An updated review of its use in the management of schizophrenia
- Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhea
- Pharmacokinetics and tissue distribution of olanzapine in rats
- Development of a stability-indicating HPLC method for simultaneous determination of olanzapine and fluoxetine in combined dosage forms
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.